Diana is the CEO & Founder of vera AI. She is a human-centred design engineer in practice and has experience with well-known companies such as Microsoft, GSK, Richemont and Holition. With an MSc/MA in Innovation Design Engineering, she extended her AI conversational agent design research during her time at the Well-being Technologies Lab, Imperial College London. She recently won the Young Innovators Award UK 2023 granted by Innovate UKContact
Diana started vera AI research during her masters at Imperial College London, after she went through several years of PCOS misdiagnosis, developing an interest in hyper-personalised care. Federico shared the same vision on the future of healthtech and together co-founded vera AI – a novel platform aiming to transform hormonal and gynaecological health management through AI hyper-personalised guidance.
Diana is the CEO & Founder of vera AI. She is a human-centred design engineer in practice and has experience with well-known companies such as Microsoft, GSK, Richemont and Holition. With an MSc/MA in Innovation Design Engineering, she extended her AI conversational agent design research during her time at the Well-being Technologies Lab, Imperial College London. She recently won the Young Innovators Award UK 2023 granted by Innovate UK.
Transforming hormonal & gynaecological health management through AI hyper-personalised guidance.
“Femtech, digital health, health-tech
Currently UK & EU, aiming to expand to the US market”
“Innovate UK Grant (non-equity) £13k
Sterling Road Grant (non-equity) £1k
Family/ friends (non-equity) £2k”
London, United Kingdom
“On average, women and menstruating persons struggle to get the right diagnosis on time when it comes to their gynaecological and hormonal health. According to the WHO, up to 70% of women who experience PCOS symptoms remain undiagnosed worldwide. On the other hand, the Royal College of GPs request personalised patient dashboards by 2030 in order to keep up with demand. With 71% of Gen Z and Millennials relying on unverified social media information and search engine results for health advice, there is an accelerated demand for access to personalised digital health solutions.
Our research at Imperial College London identified a pattern during our interviews with patients and medical staff, which we named the 4M process:
Misinformation -> Miscommunication -> Misunderstanding -> Misdiagnosis.
At vera AI, we are aiming to tackle this process, by improving access to tailored guidance, education and consultation preparation, whilst reducing professional overwhelm. “
As a data-driven software platform, vera AI aims to transform women’s health management through AI hyper-personalised guidance. With the power of generative AI, ML models and interactive UX, we are building a tailored patient health assistance that decodes unique hormonal profiles, curating content and guidance to patient needs, before, during and after consultations.
“B2C: vera AI will be available in both web and mobile app format, linked to any user device. It will generate revenue through a subscription based model with monthly and yearly plans. Subscriptions will range dependent on the different features that users want to unlock. We are targeting customers within the 18-35 years old range, later expanding to 35+ targeting perimenopause and menopause symptoms monitoring.
B2B: The next phase is built upon the development of novel hyper-personalised patient dashboards, which provide tailored hormonal profiles that the private and public healthcare system can use to enhance their diagnostic process in condition prediction and prevention, ultimately accelerating the diagnosis time. We aim to develop an ethical data monetisation model, to further contribute to medical research, medical training and development of treatments for hormonal and gynaecological health. “
As the Femtech market keeps expanding, there are a few indirect and direct competitors, such as: Flo, Natural Cycles, Hormona, Thriva and Elvie. However, vera AI provides novel features that stand out against these, including: advanced generative AI & ML data analytics tailored to each user, is a non-invasive solution that does not require wearables, additional devices or testing kits to work accurately, and provides generative AI tailored conversational assistant support 24/7. With our patient-centric design skills and AI expertise, we are co-designing our solution with our Customer Advisory Board, creating the desired next gen digital health solution.
“Active team size: currently 4 members (co-founders, a data scientist and a UX/UI designer)
Traction: 200+ customers signed up to our vera AI Community & Waitlist, with 30 officially signing up to our Customer Advisory Board.
Milestones: Research foundation built in co-design sessions with GPs, healthcare researchers and medical anthropologists, as well as 60+ participants that continously test our concept development and lo-fi prototypes. Innovate UK & Sterling Road grants help us to finalise our first MVP demo and deploying the roadmap for the second version by listening closely to our Customer Advisory Board. We were invited to take part in several community engagement events such as exhibitions, conferences, talks, and received showcasing sponsorship from Silicon Milkroundabout UK Tech Event 2023.
Market Data: Femtech is a market on a rise, globally accounting for more than $40 billions in 2020, whilst digital health solutions discussing hormonal health is predicted to reach an exponential growth of $221 billions in the upcoming years. The core locations we aim to target, UK, EU and US are one of the strongest markets for telemedicine solutions, with a tremendous projected demand of customers aged 18-40 for convenient digital health solutions. With 1 in 10 women being affected by PCOS in the UK alone, we are currently aiming to target customers interested in taking control of their hormonal and gynaecological health, within the 18-35 years old range, later planning to expand to 35+, targeting perimenopause and menopause symptoms.
Investors (Angel, VCs, early stage, pre-seed) interested in: AI healthcare, women’s health, femtech, hormonal health, digital health, generative AI and predictive AI applications.
Accelerators point of contact/ advisors: Y combinator, PlugandPlay, Health2047, QB3, etc.
Medical Advisory Board/ Potential Partners/ Collaborators: doctors & researchers specialised in gynaecology, hormonal health, endocrinology, women’s health – from private or academic backgrounds (such as Stanford).
AI & Tech Advisors / Digital Health Advisors from private or academic backgrounds
Data & Regulations Experts, International Trade: advice on AI healthcare services, femtech, data protection & encryption
Women’s health advocates/ Femtech Community: NGOs, research centers